Target
programmed death 1 (PD-1)
7 abstracts
Abstract
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,
Abstract
Early clues in the battle against advanced gastric cancer: How plasma ctDNA signals the effectiveness of PD-1 inhibitors with chemotherapy.Org: Gastric Cancer Center, The First Affiliated Hospital with Nanjing Medical University,
Abstract
Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Department of Pathology, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University, Atlanta, GA,
Abstract
Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China,
Abstract
Consensus molecular subtyping of colorectal cancer to demonstrate cetuximab benefit in right-sided CMS2 tumors, and pembrolizumab benefit in MSS CMS1 tumors.Org: Caris Life Sciences, Irving, TX, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School,
Abstract
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.Org: Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Servicio de Oncología Médica, Hospital Universitario de Jaén, European Institute of Oncology,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,